MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Prothena Corp PLC

Suletud

SektorTervishoid

11.69 -5.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.4

Max

12.34

Põhinäitajad

By Trading Economics

Sissetulek

1M

-58M

Müük

1.2M

2.1M

Aktsiakasum

-1.08

Kasumimarginaal

-2,729.911

Töötajad

163

EBITDA

1.6M

-65M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+340.79% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-57M

707M

Eelmine avamishind

17.26

Eelmine sulgemishind

11.69

Uudiste sentiment

By Acuity

29%

71%

78 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Prothena Corp PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2024, 22:51 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Prothena Corp PLC Prognoos

Hinnasiht

By TipRanks

340.79% tõus

12 kuu keskmine prognoos

Keskmine 54.57 USD  340.79%

Kõrge 110 USD

Madal 20 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Prothena Corp PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

6

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 12.71Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

78 / 386 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.